The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment – DocWire News

A research team from the University of Houston has found a way to use the stem cells found in fat and guide it to become a pacemaker-like cell, according to a new study.

We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release

The team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardia progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.

The researchers used what they called a standard screening strategy to test for reprogramming factors for converting human cardiac progenitor cells into pacemaker-like cells. According to their study results, the authors observed expressions of many pacemaker-specific genes, including CX30.2, KCNN4, HCN4, HCN3, HCN1, and SCN3b. The authors wrote that SHOX2, HCN2, and TBX5 (SHT5) combinations of transcription factors were much better candidate(s) in driving cardiac progenitor cells into pacemaker-like cells than other combinations and single transcription factors.

Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells, they wrote in their conclusion. SHT5 may be used as a potential stem cell therapy for sick sinus syndrome (SSS) and for other cardiac conduction diseases.

Visit link:
The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News

Top Technical Advances of 2019 – The Scientist

Artificial intelligence tackles life science

Look under the hood of many of this years headline-making discoveries in biology and youll find machine learning, a tool thats gaining ground in the life sciences thanks to growing computational power and the availability of big datasets needed for training. Among other advances in 2019, researchers reported successfully using machine learning to screen images for signs of cancer or infection by pathogens, and to identify epigenetic markers in blood samples that are associated with vascular complications in people with diabetes. Check out our special issue on AI for more examples of how the tool is transforming biology.

Even as computers take on more of the tasks once done by hand, engineers are exploring DNAs capacity to adopt a function usually associated with machines: information storage. This summer, researchers in Boston reported a way of harnessing DNA, together with CRISPR-like base editing machinery, to make a record of events inside living cells that can then be decoded via sequencing. Study coauthor Timothy Lu of MIT told The Scientist that its potential applications include detecting environmental toxins and recording developmental processes.

Another creative spin on CRISPR-Cas9 editing to come out this year is a detection device for particular DNA sequences. Here, the Cas9 enzyme is bound to an RNA and to a graphene chip and engineered not to make cuts in DNA. If the RNA-Cas9 complex connects to its target DNA sequence, it causes a change in the chips electric field and thus a positive readout. The chips developers suggest it could one day be used for quick DNA tests in clinical settings.

Among the endless variations of CRISPR scientists are engineering, one developed this year purports to reduce its off-target effects by avoiding double-strand DNA breaks. The technique, known as prime editing, uses the same Cas9 nuclease as frequently deployed in the CRISPR system but combines the enzyme with a guide RNA called pegRNA and a reverse transcriptase that initiates the addition of a new sequence or base into the genome. Once the new genetic material is incorporated into a cut strand of DNA, the prime editor nicks the unedited strand, signaling to the cell to rebuild it to match the edited strand.

As some researchers worked on their own variations of genome editing, others made an important edit of a recipe for induced pluripotent stem cells. First published by Shinya Yamanaka (now of Kyoto University) in 2006, the method overexpresses genes for four transcription factors in differentiated cells to reset them to a pluripotent state, creating what are known as induced pluripotent stem cells (iPSCs). The most important of the four overproduced factors was thought to be Oct4. But last month, researchers at the Max Planck Institute for Molecular Biomedicine announced theyd not only managed to make mouse iPSCs without tweaking Oct4 levels, but that the process was more efficient that way. If this works in adult human cells, it will be a huge advantage for the clinical applications of iPS cells, Yamanaka wrote in an email to The Scientist.

Shawna Williams is a senior editor atThe Scientist. Email her at swilliams@the-scientist.com or follow her on Twitter @coloradan.

See the original post here:
Top Technical Advances of 2019 - The Scientist

Induced Pluripotent Stem Cells Market: Latest Innovations, Drivers and Industry Key Events 2016 2021 – Market Reports Observer

The global market forinduced pluripotent stem cells (iPSCs)reached $2.1 billion in 2016. The market should reach $3.6 billion in 2021, increasing at a compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.

Report Scope:

This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of World. Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

Report Includes:

An overview of the global market for induced pluripotent stem cells. Analyses of global market trends with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Information on induced pluripotent stem cell research products, defined as all research tools including but not limited to: induced pluripotent stem cells and various differentiated cells derived from induced pluripotent stem cells; various related assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes, and many others that can be applied for the specific purpose of executing induced pluripotent stem cell research. Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth. Profiles of major players in the industry.

Get view Sample Analysis This Report:https://www.trendsmarketresearch.com/report/sample/12037

Report Summary

Its been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years. Particularly for the past five years, the global market for iPSCs has experienced a rapid growth. The market was estimated at $1.7 billion in 2015 and over $2 billion in 2016, with an average 18% growth. The overall iPSC market is forecast to continue its relatively rapid growth and reach over $3.6 billion in 2021, with an estimated compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.

Key Drivers for Market Growth

This report has identified several key drivers for the rapidly growing market: iPSC shold promising hope for therapeutic solutions for diseases without ethical issues. A series of technical breakthroughs were made in recent years for improving cellular reprogramming, differentiation and large-scale production of GMP- grade iPSCs derived cells toward clinical usability. The pharmaceutical industry needs better cell sources such as iPSC-derived functional cells for drug toxicity testing and drug screening. The U.S. government has been encouraging the marketing of stem cells, including iPSCs.

Request For Discount On This Report at:https://www.trendsmarketresearch.com/report/discount/12037

The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinsons and Huntingtons using stem cells. The provisions of grants from organizations, such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) have been encouraging for the research institutes to venture into iPSC research. Rapidly growing medical tourism and contract research outsourcing drives the Asia-Pacific stem cell market. Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize. The first human iPSC clinical trial started in August 2014, and the recent report of the first macular degeneration patient treated with the sheets of retinal pigmented epithelial cells made from iPSCs was encouraging. iPSC technology is developing into a platform for precision and personalized medicine, which is experiencing rapid growth globally. New biotechnologies such as genome editing technology are advancing iPSCs into more and better uses.

This report identifies key revenue segments for the iPSC market from various aspects. The applicationbased segments include the research, drug development and clinical markets; the product functionbased segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis. The current major revenue segment is the drug development and toxicity testing sector, but the market for regenerative medicine is the fastest growing one. The marketfor clinical applications is not fully established, but the market for the translational medicine research of iPSC is also growing very quickly.

Report Analysis: https://www.trendsmarketresearch.com/report/analysis/BCC/induced-pluripotent-stem-cells-market

Follow this link:
Induced Pluripotent Stem Cells Market: Latest Innovations, Drivers and Industry Key Events 2016 2021 - Market Reports Observer

The next 3D-printing craze? It could be functioning ‘mini-livers’ – Inverse

3D-printing human organs will save lives once perfected. Over 100,000 people are currently on a transplant waiting list, and 18 people die every day in the United States waiting to receive a transplant. If we could just print someone an organ using their own cells, they wouldnt have to wait for a donor and thered be pretty much no chance of the organ being rejected. Researchers in Brazil just successfully 3D-printed mini-livers in a lab, and they function just like a regular liver. Their research was published in late November 2019 in the journal Biofabrication.

The researchers took blood from three volunteers and reprogrammed the blood cells to turn them into pluripotent stem cells, which are able to develop into any type of cell found in the human body.

The pluripotent stem cells were then induced to become liver cells, mixed with bioink and put through the 3D printer as spheroids. Spheroids are clusters of cells, so unlike other organ tissue that has been printed by researchers in the past, they were printing with more than one cell at a time. The researchers then let the structure culture for 18 days.

When the scientists examined the culture after it growth period, they found hepatic organoids, which are essentially miniature livers. They are able to function exactly as a liver does on a smaller scale.

Ernesto Goulart, a postdoctoral fellow at the University of So Paulos Institute of Biosciences and an author of the study, claimed in a statement that their method was more successful than other methods.

Instead of printing individualized cells, we developed a method of grouping them before printing. These clumps of cells, or spheroids, are what constitute the tissue and maintain its functionality much longer, Goulart.

The tissue that was printed maintained hepatic functions longer than other liver tissue produced by 3D printing. Hepatic function is the term for how well the liver is working.

See also: How 3D-Printed Organs at the International Space Station May Cure Diseases

The researchers claim this whole process can be completed in 90 days. They claim their methods could definitely be used to print a fully functioning human liver.

We did it on a small scale, but with investment and interest, it can easily be scaled up, Goulart said.

Scientists have been getting much better at 3D-printing organ tissue and miniature versions of human organs in recent years. Scientists at Tel Aviv University were actually able to print a mini-human heart earlier this year. The bio-printing company Organovo is actually trying to have a patient receive a partial organ transplant with tissue made by a 3D printer by next year. A partial transplant would mean a portion of the organ tissue is replaced, which would in turn theoretically buy a patient a year or two before they need a transplant.

Were still years away from a scenario where people are regularly getting entirely new organs that were made using their own cells, but its not science fiction anymore. Once this technology proliferates and becomes affordable for the average person, well enter a time when people dont die waiting for transplants anymore.

Abstract:

The liver is responsible for many metabolic, endocrine and exocrine functions. Approximately 2 million deaths per year are associated with liver failure. Modern 3D bioprinting technologies allied with autologous induced pluripotent stem cells (iPS)-derived grafts could represent a relevant tissue engineering approach to treat end stage liver disease patients. However, protocols that accurately recapitulates livers epithelial parenchyma through bioprinting are still underdeveloped. Here we evaluated the impacts of using single cell dispersion (i.e. obtained from conventional bidimensional differentiation) of iPS-derived parenchymal (i.e. hepatocyte-like cells) versus using iPS-derived hepatocyte-like cells spheroids (i.e. three-dimensional cell culture), both in combination with non-parenchymal cells (e.g. mesenchymal and endothelial cells), into final liver tissue functionality. Single cell constructs showed reduced cell survival and hepatic function and unbalanced protein/amino acid metabolism when compared to spheroid printed constructs after 18 days in culture. In addition, single cell printed constructs revealed epithelial-mesenchymal transition, resulting in rapid loss of hepatocyte phenotype. These results indicates the advantage of using spheroid-based bioprinting, contributing to improve current liver bioprinting technology towards future regenerative medicine applications and liver physiology and disease modeling.

View post:
The next 3D-printing craze? It could be functioning 'mini-livers' - Inverse

Efficacy of Platelet-Rich Plasma Injections

PRP has been used in surgeries to promote cell regeneration since 1987,1,2 and a growing body of evidence shows it is a viable treatment for tendinosis.3-6 Not until recently, though, have experts researched and debated whether or not platelet-rich plasma (PRP) injections are an effective treatment for osteoarthritis.

See Osteoarthritis Treatment

Nearly all of the research investigating the use of PRP to treat osteoarthritis and other cartilage defects has been done since 2000, and the vast majority of research articles on the topic have been published since 2010.

See What Is Cartilage?

Not all studies support the use of PRP to treat osteoarthritis; however, experts who have reviewed the existing body of research believe the evidence is largely encouraging and merits further investigation.7-9

See Stem Cell Therapy for Arthritis

advertisement

Researchers studying PRP and osteoarthritis often work with patients who have knee osteoarthritis, a condition that experts estimate will affect nearly half of all Americans at some point during their lives.10 Two clinical studies that examine PRP to treat knee arthritis are described below.

The platelet-rich plasma used in this clinical study had 3 times the platelet concentration of normal blood and had been filtered to remove white blood cells.

While knee cartilage did not seem to regenerate for patients, the fact that the arthritis did not worsen may be significant. Evidence suggests that an average of 4 to 6% of cartilage disappears each year in arthritic joints.13,14

advertisement

Not all clinical studies provide evidence that PRP alleviates osteoarthritis symptoms. In several clinical studies PRP injections were no better than a placebo treatment. Even in studies that do provide evidence that PRP works, not all patients benefit.

See Is Stem Cell Therapy for Arthritis Safe and Effective?

PRP proponents assert that PRP fails to successfully treat symptoms in some cases because of differences in PRP formulation or injection administration - in other words, certain changes in variables, such as PRP preparation methods, the amount of PRP injected, and the frequency of injections, can make the PRP less effective. Others suggest that PRP therapy may be a passing fad that has limited value.15,16

It may be that PRP therapy, like other osteoarthritis treatments, works for some people but not for others, or works best in conjunction with other treatments, such as physical therapy.

Read more: Knee Exercises for Arthritis

Read more here:
Efficacy of Platelet-Rich Plasma Injections

In case you missed them: Spectrum’s standout stories from 2019 – Spectrum

Spectrum published hundreds of articles this year on a range of topics, from characterization of candidate genes to immune-system connections. We are proud of all of them, but some in particular stand out: They expose harmful therapies such as chiropractic and stem-cell treatments, upend conventional wisdom about autism, expose uncomfortable truths or adroitly explain complex theories about the condition.

Our staff and some of our readers picked the following seven as particular favorites from the year.

Autism, explained

How might a brain-signaling imbalance underlie autism? What is the female protective effect and, conversely, an extreme male brain? We expanded our compendium of autism explainers this year to include some of the most popular theories about the condition.

False hope for autism in the stem-cell underground

Clinics offering stem-cell treatments for autism are proliferating, and desperate parents pay thousands of dollars to have these products injected into their children despite a lack of evidence that they help. Many, in fact, have the potential to cause serious harm, from introducing life-threatening infections to seeding autoimmune disorders. In this story, investigative reporter Brendan Borrell traces the provenance of one childs treatments through a cast of rogue characters and calls attention to the fact that the products are, as one of his sources says, basically afterbirth thrown in a blender.

Can preventing seizures alter the course of autism?

This story sprang to life when reporter Jessica Wright observed experimental brain surgery on a 12-year-old boy named Kevin Lightner. Kevin has dup15q syndrome, a rare genetic condition that often causes seizures and autism, and his case presented a prime opportunity to explore a provocative question: Can epilepsy lead to or at least contribute to autism? Wright followed Kevin and his family through a risky procedure to implant a responsive neurostimulation device into his brain, and over the weeks that followed.

When autistic people commit sexual crimes

Many autistic people become embroiled in the criminal justice system for sexual behaviors, including collecting child pornography, stalking and sexual assault. Some go to prison, and others become registered sex offenders a status that can prevent them from receiving state services for the rest of their lives. But as Melinda Wenner-Moyer explores in this story, autistic people may engage in these behaviors without understanding the implications of their actions or the law. Some experts are calling for a change in how the criminal justice system treats these autistic people, and for more sexual education for autistic teens.

Autism, through the eyes of a computer

Clinicians are the main arbiters of autism traits. They use their expertise to diagnose autism and judge its severity. But a growing cadre of scientists is betting that computers could do some parts of these tasks better. In this story, reporter Nicholette Zeliadt explores the use of wearable sensors and other devices to track autism traits over time as they collect data from autistic people in their homes and schools. These measurements may never replace the judgment clinicians hone through years of experience, but they may ease the workload of experts and the wait time for people who need evaluations.

Large study supports discarding the term high-functioning autism

Autistic people who excel academically are sometimes referred to as high functioning. The problem is, many dont function at all well: They struggle with everyday tasks, from getting dressed to taking the bus. This story underscores the gaping chasm between intelligence and daily living skills, and the crescendo of voices calling to abandon the high functioning label.

Studies of autism treatments lack standard yardsticks

An analysis of 36 years of clinical trials showed that researchers do not use a consistent set of tools to measure the efficacy of autism treatments. Nearly 70 percent of the tools were used in just one study, making it difficult to compare the treatments. And only three validated tools that measure core autism traits were used in more than 5 percent of the studies. But these tools are not designed to measure treatment outcomes, so they may miss subtle signs that a drug, dietary supplement or psychotherapy is working.

Follow this link:
In case you missed them: Spectrum's standout stories from 2019 - Spectrum

Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients – P&T Community

NESS ZIONA, Israel, Dec. 23, 2019 /PRNewswire/ --Kadimastem Ltd.(TASE: KDST), a clinical stage cell therapy company, today announced that treatment with a single dose of 250x10[6] AstroRxcells to all 5 ALS patients in cohort B has been completed.

The primary objective of the trial is to evaluate the safety of injecting AstroRx, an "off-the-shelf" clinical-grade astrocyte cell product, developed and manufactured by the Company, into the cerebro-spinal fluid (CSF) of ALS patients. A secondary objective of the trial includes preliminary efficacy.

The clinical trial is progressing as planned. Cohort B patients will be monitored for 6 months following treatment.In addition, the first patient of cohort C has already been enrolled. Cohort C is designed to assess long term safety and efficacy of a repeated dose administration of AstroRxin 2 consecutive injections separated by an interval of 2-3 months. As previously reported in September 2019, positive interim results of cohort A demonstrated safety and statistically significant preliminary efficacy of a single dose of 100x10[6] AstroRxcell administration. In light of these positive results, the company is taking the necessary steps to obtain approval to a proposed protocol amendment according to which the repeated administration will comprise of the same dose (100x10[6]).

Results of cohort A and B are expected to be reported as planned and as previously announced, by the end of 2019 and during August 2020, accordingly. Results of cohort C are expected in the first half of 2021.

Rami Epstein, CEO of Kadimastem, commented: "Completing treatment for the additional 5 ALS patients in Cohort B, for a total of 10 patients treated with our product in our clinical trial, serves as an additional demonstration of our ability to develop and produce high quality clinical grade cells and takes us a significant step forward in our path to bringing innovative cure to ALS. The expected completion of cohort B 6-months follow-up period will allow us to assess the safety and preliminary efficacy of 250x10[6]cells, compared to that of the lower dose administered in cohort A."

Prof. Michel Revel, Founder and CSO of the Company, added: "The results of the next treatment group, Cohort C, in which each patient will be treated with 2 consecutive injections separated by an interval of 2-3 months,will allow us to assess the possible prolonged efficacy of the repeated dose, compared to the single dose treatment provided in cohorts A and B. The results that will be obtained from the different cohorts, will support us in the process of defining the dose and treatment regimen that will lead to most favorable results for patients over time."

About AstroRx

AstroRxis a clinical grade cell therapy product developed and manufactured by Kadimastem in its GMP-compliant facility, containing functional healthy astrocytes (nervous system support cells) derived from human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons through several mechanisms of action. The Company's technology enables the injection of AstroRxcells into the spinal cord fluid of patients suffering from Amyotrophic Lateral Sclerosis (ALS) with the goal of supporting the malfunctioning cells in the brain and spinal cord, in order to slow the progression of the disease and improve patients' quality of life and life expectancy. AstroRxhas been shown to be safe and effective in preclinical studies. AstroRxhas been granted orphan drug designation by the FDA.

About ALS

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease causing disfunction in the upper and lower motor nerves that control muscle function. ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is 2-5 years. According to the ALS Therapy Development Institute, it is estimated that there are approximately 450,000 ALS patients worldwide of which 30,000 reside in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to US$ 6 Billion.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic proprietary cell products based on its platform technology for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells. AstroRx, the Company's lead program, is a clinical-grade astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. In addition, preclinical trials are ongoing with the Company's IsletRx pancreatic functional islet cells for the treatment of insulin dependent diabetes. Kadimastem was founded by Prof. Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Prof. Revel received the Israel Prize for the invention and development of Rebif, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Forward Looking Statement

This document may include forward-looking information as defined in the Securities Law, 5728 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developmentsin the general environment and external factors affecting the Company's activity. The Company's results and achievements in the futuremay differ materially from any presented herein and the Company makes no undertaking to update or revise such projectionor estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should take into account that past performance does not necessarily indicate performance in the future.

Company Contacts:

Yossi Nizhar, CFO y.nizhar@kadimastem.com+972-73-797-1604

Investor Relations and Financial Media Meirav Gomeh-Bauer meirav@bauerg.com+972-54-476-4979

Global Media & Collaborations Dasy Mandel, Director of Business Development d.mandel@kadimastem.com +972-73-797-1613

View original content:http://www.prnewswire.com/news-releases/kadimastem-announces-the-completion-of-treatment-for-cohort-b-of-its-phase-12a-clinical-trial-in-als-patients-300979013.html

SOURCE Kadimastem

More:
Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients - P&T Community

Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. – Market Research Sheets

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

This post was originally published on Market Research Sheets

Read the rest here:
Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. - Market Research Sheets

Leukaemia and lymphoma have a good survival rate – The Star Online

Of all blood cancers, leukaemia and lymphoma are among the most curable.

However, many people, including doctors, still believe the disease leads to immediate death.

This is no longer true today as they are not fatal.

With optimal treatment, the majority of patients go into remission and are considered cured.

These two cancers have been more extensively studied than other forms of cancer, due to the ease in obtaining samples from blood, bone marrow or lymph nodes, spurring the advent of novel targeted therapies for a cure, says consultant haematologist Dr Ng Soo Chin.

Most blood cancers start in the bone marrow, where blood is produced.

Bone marrow contains stem cells, which mature and develop into red blood cells, white blood cells or platelets.

In most blood cancers, normal cell development is interrupted by the uncontrolled growth of an abnormal type of a particular blood cell.

These abnormal blood cells, which are cancerous, prevent your blood from performing many of its functions, like fighting off infections or preventing serious bleeding.

Leukaemia or white blood is classified into acute and chronic disease, which is then divided further into subtypes: acute lymphocytic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML).

The presentation between acute and chronic leukaemia differs.

The acute person will tell you he was well a week ago and is now down with symptoms such as lethargy, anaemia and recurrent infection.

Suddenly, he may look pale, so we check his blood count for any abnormalities. A bone marrow exam will further confirm whether it is acute.

With chronic leukaemia, the patient can be unwell for a couple of months.

We are increasingly picking up cases early because of blood test availability.

The survival rate has improved tremendously for acute leukaemia, with more than 50% fully cured because bone marrow transplants are easily available in the country.

For CLL and CML, 95% of patients are alive at the 10-year mark, says Dr Ng.

Generally, chronic leukaemia patients belong to the older age group (50 years and above), but acute leukaemia can occur in all ages.

Leukaemia symptoms are often vague and not specific, so its easy to overlook them as they may resemble symptoms of the flu and other common illnesses.

In fact, chronic leukaemia may initially produce no symptoms and can go unnoticed or undiagnosed for years.

Lymphomas, a type of blood cancer that begins in a subset of white blood cells called lymphocytes, can be classified into Hodgkins and non-Hodgkins.

The main difference between Hodgkins and non-Hodgkins lymphoma is the specific lymphocyte each involves.

Lymphocytes are an integral part of your immune system, which protects you from germs.

Five-year survival rates are high with Hodgkins lymphoma at 86% and non-Hodgkins lymphoma at 70%.

You can beat the disease even if it is detected at a late stage.

Multiple myeloma, which is the third kind of blood cancer, forms in a type of white blood cell called a plasma cell.

Patients often complain of bone pain, and unfortunately, this type of cancer has no cure.

Blood cancers typically involve abnormal white blood cells and can affect paople of all ages, depending on the type of cancer. 123rf.com

Fear of treatment

Chemotherapy is a much dreaded word among cancer patients.

But with advances in medicine, newer chemotherapy-free treatments are now available.

Dr Ng says, Traditionally, cancer is treated via surgery or radiation the layman says we fry and poison them, which is not far from the truth!

Radiation means burning the cancerous area, but a lot of times, the cancer can also be present elsewhere, so there is limitation to this treatment.

With chemotherapy, we use cytotoxic (cell-killing) drugs they go in and knock off both cancer and normal cells.

The short-term effects include vomiting, hair loss, appetite loss and weight loss.

But as doctors, we are looking at a different perspective. We are more worried about white cells dropping (neutropenia) because the patient can pick up an infection that can potentially kill him.

Neutropenia is a condition that results when the body does not have enough neutrophils, a type of white blood cell that is an essential first line of defence against infections.

Thats one risk of chemotherapy, although we can now improve neutropenia by giving a growth factor injection.

But for certain cancers, we need to step up the drugs.

He adds: We are scared of neutropenia, but patients are more concerned about bodily changes.

The older ones get upset over losing hair because they cannot take it when others ask them what has happened to their hair.

Young people are not as concerned with hair loss because it can be trendy.

We understand that chemotherapy is less than pleasant and strong doses can impair fertility in young patients, especially women.

Despite current technology, only one-third of patients are successful in freezing their eggs.

What he is concerned about is that chemotherapy can actually increase the patients risk of getting another cancer, especially blood cancer.

It can happen the day after! says Dr Ng.

Most experts believe chemotherapy damages stem cells, so if youre unlucky, you might get acute myeloid leukaemia after undergoing chemotherapy for breast cancer.

Its just like crossing the road there is always a risk of being knocked down.

All our cells have a biological clock and there is an orderly exchange of old and new cells.

But with blood cancers such as leukaemia, there is a clone of abnormal cells.

Cancer cells have an advantage over normal cells because they can survive longer.

Chemotherapy is still needed to treat most acute blood cancers, although if the mutation is known, targeted therapies can be applied.

For chronic blood cancers, there is no need for chemotherapy. Oral drugs are enough to combat the disease.

Eventually, many patients are able to wean off the drugs.

As we may be aware, immunotherapy is the buzzword in cancer treatment today.

Also called biologic therapy, it is a type of cancer treatment that boosts the bodys natural defences to fight cancer.

It uses substances made by the body or in a laboratory to improve or restore immune system function.

One of the latest treatment modalities is the CAR T-cell therapy, a form of immunotherapy that uses specially altered T cells a part of the immune system to fight cancer.

A sample of a patients T cells are collected from the blood, then modified to produce special structures called chimeric antigen receptors (CARs) on their surface.

When these CAR T-cells are reinfused into the patient, the new receptors enable them to latch onto a specific antigen on the patients tumour cells and kill the cells.

At the moment, this intravenous therapy is available in the United States and hasnt reached our shores yet. It has to be properly regulated first, says Dr Ng.

A volunteer is having his head shaved to donate hair to make wigs for cancer patients in this filepic. Hair loss is one of the side effects of chemotherapy that affect patients the most.

Following natural remedies

The consultant haematologist errs on the side of caution when patients ask about natural cancer remedies, or the dos and donts during treatment.

We always believe there should be a scientific approach to the problem.

If patients are doing okay while undergoing treatment and there is no weight loss, I tell them to go ahead and do what they always do.

However, just be particular about food hygiene, as there is a chance you may get food poisoning.

If youre undergoing chemotherapy, then youll land yourself in hospital, and if your luck is bad, you may even land up in the ICU (intensive care unit).

So make sure the food is cooked and not left overnight to reduce your chances of infection.

Eat a balanced diet, he advises.

When it comes to exercise, he says to work out within your limit.

Instead of pushing the body and running marathons or climbing mountains, go for walks.

Dr Ng says, Life should go on, but be sensible.

Dont go to crowded places because you may pick up an infection, but dont be withdrawn either. All humans need social interaction.

With the billion-dollar dietary supplements industry, companies are constantly trying to lure customers into buying their products.

A lot of supplements are just glorified vitamins in different packaging.

The more expensive they are, the more people will buy them, thinking they are good.

There are people with good intentions, but unfortunately, there are also a lot of scammers out there that is life.

For the amount you spend on supplements, why not keep the money aside and go for a trip once your treatment is over? he suggests.

Often, the late diagnosis is due to preference for alternative treatment.

These alternative treatments are like fashion shows, after some time, they go out of trend.

For me, youre wasting valuable time because cancer is not your friend.

Yes, chemotherapy is tough, but with the latest chemo-free regimen, patients are more willing to come forward.

The earlier it is treated, the higher your chances of recovering, he says.

To share his 30-odd years of knowledge and experience in the field, Dr Ng has written his third book titled Understanding Blood Disorders.

Intended for patients, caregivers and healthcare professionals, proceeds from the sales of the 270-page book will go to the newly set-up Faith Hope Love Hospice Care Malaysia in Petaling Jaya, Selangor.

We're sorry, this article is unavailable at the moment. If you wish to read this article, kindly contact our Customer Service team at 1-300-88-7827. Thank you for your patience - we're bringing you a new and improved experience soon!

Article type: metered

User Type: anonymous web

User Status:

Campaign ID: 7

Cxense type: free

User access status: 3

Visit link:
Leukaemia and lymphoma have a good survival rate - The Star Online

Pike River widow credits granddaughter with getting her through cancer ‘battle’ – Stuff.co.nz

Pike River widow Anna Osborne is creditingher granddaughter withhelpingher get through invasive cancer treatment.

Osborne, whose husband Milton died West Coastmine disaster just over nine years ago, had stem-cell replacementforHodgkinlymphoma in October.

She was told she had a four weeksto a year to live without the risky surgery, or up to five years with it. Wanting to see 2-year-old grandaughter Amalia start school was a big factor in thedecision to push ahead.

Supplied

Anna Osborne and her two-year-old granddaughter, Amalia, who Osborne says has been her inspiration to prolong her life after fighting cancer.

Her stem-cells wereharvested and frozenin August. The stem cell transplanttook place in Christchurch in October aftersix days of intensive chemotherapy.

READ MORE:*Pike River mine tunnel entry an important moment for widow*Pike River re-entry team breaks through into mine drift*Pike River widow 'full of nerves' for mine drift re-entry*The road to getting back into Pike River

"It kills everything.It was pretty rough going," Osborne told Stuff from herhospital bed in Greymouth.

Joanne Carroll/Stuff

Osborne has undergone a stem cell transplant, but has been in and out of hospital during her recovery.

"It was a long and really difficult process because I became really really ill. Vomiting, sleeping all the time. If I caught an infection it could kill me."

After the successful transplant of her stem-cells back into her body, she stayed in Christchurch'stransplant unit forfive weeks.

She was then transferred to Grey Base Hospital.

Phil Walter/Getty

Osborne greeting Prime Minister Jacinda Ardern when the Pike River re-entry got under way in May.

"I've been home threetimes from hospital, only two days each time. On the second day, I've just gone right down again and got nothing left to give,so I'm backin hospital. It's been a bit of a battle."

She has no appetite, is nauseousand and unable to retain some nutrients.

"My bloods might be normal but then very quickly I can't retain any electrolytes and I go down hill and everything is depleted.

Kevin Stent/Stuff

Osborne, left, with friend and fellow Pike River family member Sonya Rockhouse.

"It's a hard road. You're sick of being sick ...sick of having no energy.

"I know in the end it's going to be worthwhile and I've bought myself another four or five years. Hopefully a lot longer than that."

Osbornewasdiagnosed with the cancer, which attacks theimmune system,in 2002 at age 36.

Stacey Kirk/Stuff

Representatives of some of the Pike River families - Anna Osborne, Sonya Rockhouse and Bernie Monk - talk of their elation at the decision to re-enter the mine. (First published November 2018)

She had radiation for six weeks and went into remission, but the cancercame back just before the Pike River tragedy in November 2010, when 29 men where killed in a series of explosions at the coal mine. Osborne helped campaign for thelegalisation of medicinal cannabiswhile undergoing chemotherapy in 2015.

She is awaiting a full scan to see if the treatment has removed all the tumours in her body. For now, she is taking each day as it comes.

"I'm feeling quite positive. I've got four or five years left in me. You've got to remain positive. It's easy to give up," she said.

At her darkest moments, Amalia was at the forefront of her mind.

"She needs me and I need her. I want to be there when she starts school. She was the person that got me through and made me want to keep going.

"She's magnificent. She's brightened my world ... it's really nice having her to keep going for."

Osborne said she had a special bond with Amalia.

"She will bring her blankie and baby and sit on my lap and just cuddle into me, and my daughter says she doesn't do that for anyone.

"I can't give up on that,it's too beautiful."

Link:
Pike River widow credits granddaughter with getting her through cancer 'battle' - Stuff.co.nz